UNSPSC 51182425: Butedronic acid

This classification denotes a bone resorption inhibitor and biphosphonate, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26PB1U68YF. European Medicines Agency schedules Butedronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06011MIG. Butedronic acid generally arises in the molecular formula C5H10O10P2.

The term BUTEDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 3, no. 3, 1989, list 29.) As of Q4 2014, BUTEDRONIC ACID remains the US FDA Preferred Term for this commodity. Butedronic acid bears US NLM identifiers UMLS ID C2347239 and NCI Concept Code C72092. SMILES: P(=O)(O)(O)C(P(=O)(O)O)C(CC(=O)O)C(=O)O.

UNSPSC 51182425 Butedronic acid is a Commodity code capturing pharmaceutical products solicited through state and local cooperative purchasing vehicles for distribution across participating government facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses this code family to procure generic multi-source pharmaceuticals and over-the-counter products for use across state and local government health and corrections facilities. State and local buying under this code reflects the reality of modern government pharmaceutical procurement: vendors supply products through a pre-approved wholesaler network (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) rather than directly to end-use agencies, with contracts structured around fixed pricing, net price formats, or WAC-minus pricing. Vendors must hold current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, maintain contractual relationships with at least two of the three authorized wholesalers, and carry commercial general liability insurance of $5,000,000 per occurrence plus network security and privacy liability coverage.

The most recent representative opportunity is MMCAP's January 2026 RFP (S1070000015802) to establish multiple-award contracts for generic pharmaceuticals and OTC products, with proposals due March 26, 2026 and contract performance beginning July 1, 2026 across Minnesota, Oregon, and other participating states. The RFP evaluates vendors primarily on price competitiveness (75 percent weight), with the remaining 25 percent split among fixed pricing compliance, administrative fee format adherence, EDI capability, and agreement to a 3 percent administrative fee on all contract purchases. No specific dollar ceiling or award value range is disclosed in the solicitation. The contract term runs two years for new vendors with optional extensions at MMCAP's discretion, while incumbents' amendments extend through June 30, 2028. Award structure is flexible — MMCAP reserves sole, dual, or multi-award authority based on therapeutic need, product availability, and member-specific requirements.